“
“Sequential therapy has been recommended in the Maastricht https://www.selleckchem.com/products/NVP-AUY922.html IV/Florence Consensus Report as the first-line treatment for Helicobacter pylori eradication in regions with high clarithromycin resistance. However,

it fails in 5–24% of infected subjects, and the recommended levofloxacin-containing triple rescue therapy only achieves a 77% eradication rate after failure of sequential therapy. To investigate the efficacy of a novel quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin for rescue treatment of sequential therapy. This was a multicenter study in which H. pylori-infected patients who had failed sequential therapy received a 10-day quadruple therapy (esomeprazole (40 mg b.d), tripotassium dicitrato bismuthate (120 mg q.d.s.), tetracycline (500 mg q.d.s.), and levofloxacin (500 mg o.d.) for 10 days). H. pylori status

was examined 6 weeks after the end of treatment. From July 2007 to June 2012, twenty-four subjects received 10-day quadruple therapy. The eradication rates according to intention-to-treat and per-protocol analyses were both 95.8% (23 of 24; 95% confidence interval, 87.8–103.8%). Adverse events were seen in 25.0% (6 of 24) of the patients. Drug compliance was 100.0% (24/24). The 10-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a very high eradication rate for Anti-infection Compound Library H. pylori infection after failure of sequential therapy. It is well tolerated and has great potential to become a good choice of rescue treatment following non-bismuth-containing quadruple therapy in regions with high clarithromycin resistance. Helicobacter pylori infection (H. pylori) is the main cause of gastritis, gastroduodenal ulcer disease, gastric adenocarcinoma,

and mucosa-associated tissue lymphoma. Standard triple therapy has been recommended as first-line regimen for H. pylori infection in main international guidelines [1, 2]. However, several large clinical trials and meta-analyses have shown that the eradication rate of the standard therapy has generally declined to unacceptable levels (i.e., 80% or less) recently [3, 4]. In some European countries, the success rates are disappointingly low with values only 25–60% [5, 6]. Therefore, several novel first-line therapies including sequential therapy, concomitant therapy, and hybrid therapy have emerged to treat Fossariinae naive H. pylori infection [7-9]. The Maastricht IV/Florence Consensus Report [10] has recommended treatment for H. pylori infection according to antibiotic resistance rates in local areas recently. In some countries with low clarithromycin resistance of H. pylori, standard triple therapy is still the best option, but bismuth-containing quadruple therapies such as sequential therapy and concomitant therapy are the preferred option in countries with clarithromycin resistance >20%. Sequential therapy is a promising therapy achieving an eradiation rate of 90–94% [7, 11-13].